Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma

doi:10.3748/wjg.v28.i36.5250

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 36

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5618)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

293

WORD

HTML

3106

Figures (1-2)

429

Tables (1-3)

458

Sum=4358

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

379

Download

881

Sum=1260

Sep 28, 2022 (publication date) through Feb 8, 2025

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Sep 28, 2022; 28(36): 5250-5264
Published online Sep 28, 2022. doi: 10.3748/wjg.v28.i36.5250

Table 3 Clinical trials of transforming growth factor-beta 1 blockade with Galunisertib in hepatocellular carcinoma and other cancers

Drug	Title of the study	Treatment	Phase	Status	Trial ID
Galunisertib	A study of Galunisertib on the immune system in participants with cancer	Monotherapy	Phase I	Completed	NCT02304419
Galunisertib	Galunisertib (LY2157299) and stereotactic body radiotherapy in advanced hepatocellular carcinoma	Combination with radiotherapy	Phase I	Completed	NCT02906397
Galunisertib	A study of LY2157299 in participants with unresectable hepatocellular cancer	Combination with Nivolumab	Phase II	Completed	NCT02423343
Galunisertib	A study of LY2157299 in participants with unresectable hepatocellular cancer	Combination with Sorafenib	Phase I	Completed	NCT02240433
Galunisertib	A study of LY2157299 in participants with advanced hepatocellular carcinoma	Combination with Sorafenib	Phase II	Completed	NCT02178358
Galunisertib	A study of LY2157299 in participants with hepatocellular carcinoma	Combination with Sorafenib/Ramucirumumab	Phase II	Completed	NCT01246986
Galunisertib	Galunisertib and Capecitabine in advanced resistant TGF-beta activated colorectal cancer (EORTC1615)	Combination with Capecitabine	Phase II	Withdrawn	NCT03470350
Galunisertib	A study of LY2157299 in participants with pancreatic cancer (advanced or has spread to another part of the body)	Combination with Gemcitabine	Phase I	Completed	NCT02154646
Galunisertib	A study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in participants with metastatic pancreatic cancer	Combination with Durvalumab	Phase I	Completed	NCT02734160

TGF: Transforming growth factor.

Citation: Devan AR, Pavithran K, Nair B, Murali M, Nath LR. Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma. World J Gastroenterol 2022; 28(36): 5250-5264
URL: https://www.wjgnet.com/1007-9327/full/v28/i36/5250.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i36.5250